CALCA and migraine disorder: There are currently four CGRP mabs that are used for migraine prevention: erenumab 70 mg or 140 mg subcutaneously (SC) monthly, fremanezumab 225 mg SC monthly and 675 mg SC quarterly, galcanezumab 240 mg SC loading dose followed by 120 mg SC monthly and eptinezumab 100 mg or 300 mg intravenously (I.V.)quarterly (2–5).